{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:21:31Z","timestamp":1785349291899,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T00:00:00Z","timestamp":1564358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pearl \u2013 a member of the AstraZeneca Group","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12931-019-1126-7","type":"journal-article","created":{"date-parts":[[2019,7,29]],"date-time":"2019-07-29T14:03:34Z","timestamp":1564409014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Bone and ocular safety of budesonide\/glycopyrrolate\/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study"],"prefix":"10.1186","volume":"20","author":[{"given":"Edward M.","family":"Kerwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary T.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiernan","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dorinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,29]]},"reference":[{"key":"1126_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. 2019 Report: Global Strategy for Prevention, Diagnosis and Management of COPD 2019.\n                    https:\/\/goldcopd.org\/\n                    \n                  . Accessed 11 Apr 2019."},{"key":"1126_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747\u201358.","journal-title":"Lancet Respir Med"},{"key":"1126_CR3","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671\u201380.","journal-title":"N Engl J Med"},{"key":"1126_CR4","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1183\/09031936.06.00024605","volume":"27","author":"DM Mannino","year":"2006","unstructured":"Mannino DM, Watt G, Hole D, Gillis C, Hart C, McConnachie A, et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J. 2006;27:627\u201343.","journal-title":"Eur Respir J"},{"key":"1126_CR5","doi-asserted-by":"publisher","first-page":"ORSF5","DOI":"10.1167\/iovs.13-12789","volume":"54","author":"R Klein","year":"2013","unstructured":"Klein R, Klein BEK. The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Invest Ophthalmol Vis Sci. 2013;54:ORSF5\u2013ORSF13.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1126_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s001980200001","volume":"13","author":"L Warming","year":"2002","unstructured":"Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int. 2002;13:105\u201312.","journal-title":"Osteoporos Int"},{"key":"1126_CR7","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1378\/chest.128.4.2099","volume":"128","author":"JB Soriano","year":"2005","unstructured":"Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128:2099\u2013107.","journal-title":"Chest."},{"key":"1126_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1513\/pats.200709-148ET","volume":"5","author":"WM Chatila","year":"2008","unstructured":"Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549\u201355.","journal-title":"Proc Am Thorac Soc"},{"key":"1126_CR9","first-page":"1331","volume":"10","author":"J Milkowska-Dymanowska","year":"2015","unstructured":"Milkowska-Dymanowska J, Bialas AJ, Zalewska-Janowska A, G\u00f3rski P, Piotrowski WJ. Underrecognized comorbidities of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1331\u201341.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"1126_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.11005\/jbm.2016.23.3.111","volume":"23","author":"R Okazaki","year":"2016","unstructured":"Okazaki R, Watanabe R, Inoue D. Osteoporosis associated with chronic obstructive pulmonary disease. J Bone Metab. 2016;23:111\u201320.","journal-title":"J Bone Metab"},{"key":"1126_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","volume":"69","author":"SI Rennard","year":"2009","unstructured":"Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, et al. Efficacy and tolerability of budesonide\/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69:549\u201365.","journal-title":"Drugs."},{"key":"1126_CR12","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1378\/chest.08-3016","volume":"136","author":"GT Ferguson","year":"2009","unstructured":"Ferguson GT, Calverley PMA, Anderson JA, Jenkins CR, Jones PW, Willits LR, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a revolution in COPD health study. Chest. 2009;136:1456\u201365.","journal-title":"Chest."},{"key":"1126_CR13","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1183\/09031936.02.00276602","volume":"19","author":"O Johnell","year":"2002","unstructured":"Johnell O, Pauwels R, L\u00f6fdahl C-G, Laitinen LA, Postma DS, Pride NB, et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler\u00ae. Eur Respir J. 2002;19:1058\u201363.","journal-title":"Eur Respir J"},{"key":"1126_CR14","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1056\/NEJM199906243402503","volume":"340","author":"RA Pauwels","year":"1999","unstructured":"Pauwels RA, L\u00f6fdahl C-G, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. For the European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med. 1999;340:1948\u201353.","journal-title":"N Engl J Med"},{"key":"1126_CR15","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ophtha.2008.12.001","volume":"116","author":"JJ Wang","year":"2009","unstructured":"Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009;116:652\u20137.","journal-title":"Ophthalmology."},{"key":"1126_CR16","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1183\/09031936.06.00043005","volume":"27","author":"P Ernst","year":"2006","unstructured":"Ernst P, Baltzan M, Desch\u00eanes J, Suissa S. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J. 2006;27:1168\u201374.","journal-title":"Eur Respir J"},{"key":"1126_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJM199707033370102","volume":"337","author":"RG Cumming","year":"1997","unstructured":"Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8\u201314.","journal-title":"N Engl J Med"},{"key":"1126_CR18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/thx.2011.160028","volume":"66","author":"YK Loke","year":"2011","unstructured":"Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011;66:699\u2013708.","journal-title":"Thorax."},{"key":"1126_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.chest.2017.07.002","volume":"153","author":"AV Gonzalez","year":"2018","unstructured":"Gonzalez AV, Coulombe J, Ernst P, Suissa S. Long-term use of inhaled corticosteroids in COPD and the risk of fracture. Chest. 2018;153:321\u20138.","journal-title":"Chest."},{"key":"1126_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3109\/15412555.2013.795423","volume":"10","author":"NK Leidy","year":"2013","unstructured":"Leidy NK, Murray LT. Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD. 2013;10:393\u20138.","journal-title":"COPD."},{"key":"1126_CR21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.rmed.2014.04.015","volume":"108","author":"J Maspero","year":"2014","unstructured":"Maspero J, Cherrez I, Doherty DE, Tashkin DP, Kuna P, Kuo W-L, et al. Appraisal of lens opacity with mometasone furoate\/formoterol fumarate combination in patients with COPD or asthma. Respir Med. 2014;108:1355\u201362.","journal-title":"Respir Med"},{"key":"1126_CR22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1056\/NEJMoa063070","volume":"356","author":"PMA Calverley","year":"2007","unstructured":"Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775\u201389.","journal-title":"N Engl J Med"},{"key":"1126_CR23","doi-asserted-by":"crossref","unstructured":"Martinez FJ, Rabe KF, Ferguson GT, Fabbri LM, Rennard S, Feldman GJ, et al. Efficacy and safety of glycopyrrolate\/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151:340\u201357.","DOI":"10.1016\/j.chest.2016.11.028"},{"key":"1126_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.rmed.2017.03.015","volume":"126","author":"Nicola A. Hanania","year":"2017","unstructured":"Hanania NA, Tashkin DP, Kerwin EM, Donohue JF, Denenberg M, O'Donnell DE, et al. Long-term safety and efficacy of glycopyrrolate\/formoterol metered dose inhaler using novel Co-Suspension\u2122 Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017;126:105\u201315.","journal-title":"Respiratory Medicine"},{"key":"1126_CR25","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.2147\/COPD.S171835","volume":"13","author":"BJ Lipworth","year":"2018","unstructured":"Lipworth BJ, Collier DJ, Gon Y, Zhong N, Nishi K, Chen R, et al. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate\/formoterol fumarate metered dose inhaler in COPD: a randomized phase III study conducted in Asia, Europe, and the USA. Int J Chron Obstruct Pulmon Dis. 2018;13:2969\u201384.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1126_CR26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1183\/09031936.03.00031402","volume":"21","author":"W Szafranski","year":"2003","unstructured":"Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74\u201381.","journal-title":"Eur Respir J"},{"key":"1126_CR27","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391:1076\u201384.","journal-title":"Lancet."},{"key":"1126_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","volume":"388","author":"D Singh","year":"2016","unstructured":"Singh D, Papi A, Corradi M, Pavli\u0161ov\u00e1 I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963\u201373.","journal-title":"Lancet."},{"key":"1126_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M15-0288","volume":"163","author":"WP Battisti","year":"2015","unstructured":"Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163:461\u20134.","journal-title":"Ann Intern Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1126-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-019-1126-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-019-1126-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T23:21:36Z","timestamp":1595892096000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-019-1126-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,29]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1186\/s12931-019-1126-7","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,29]]},"assertion":[{"value":"23 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The informed consent form and study protocol were approved by an institutional review board (Schulman Associates; approval number 201503097), and patients provided written informed consent for both KRONOS and the extension study prior to screening.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EMK has served on advisory boards, speaker panels or received travel reimbursement from Amphastar, AstraZeneca, Boehringer Ingelheim, Cipla, Forest, GlaxoSmithKline, Mylan, Novartis, Oriel, Pearl \u2013 a member of the AstraZeneca Group, Sunovion, Teva, and Theravance. He has conducted multicenter clinical trials for ~\u200940 pharmaceutical companies. GTF reports grants, personal fees, and non-financial support from AstraZeneca during the conduct of the study; grants, personal fees, and non-financial support from AstraZeneca, Boehringer Ingelheim, Novartis, Pearl \u2013 a member of the AstraZeneca Group, and Sunovion; grants and personal fees from Theravance; and personal fees from Circassia, GlaxoSmithKline, Innoviva, Mylan, and Verona, outside the submitted work. MM, KDeA, and PD are employees of Pearl \u2013 a member of the AstraZeneca Group.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}